Article
HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).
British journal of clinical pharmacology - 1 Jul 2026
Galloway Lucy, Dello Russo Cinzia, Bass Nicholas, Bramon Elvira, Cross Helen, Curley Natalie, Curran Sarah, Davies Helen, De Villiers Jana, Evans William, Frank Bernhard, Groves Alice, Hayward Judith, Higham Jon, Hughes Dyfrig A, Kyaw Shwe Sin, Marson Anthony G, McLellan Ailsa, Mensah Seth, O'Neill Francis, Sargison Jane, Sisodiya Sanjay M, Swan Jill, Zakrewska Joanna M, Pirmohamed Munir
Abstract excerpt
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune-mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity. The liver and other organ systems can also be affected. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
